Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
53.82
+0.34 (0.64%)
At close: Oct 23, 2025, 4:00 PM EDT
53.82
0.00 (0.00%)
After-hours: Oct 23, 2025, 4:10 PM EDT
Apogee Therapeutics Employees
Apogee Therapeutics had 196 employees as of December 31, 2024. The number of employees increased by 105 or 115.38% compared to the previous year.
Employees
196
Change (1Y)
105
Growth (1Y)
115.38%
Revenue / Employee
n/a
Profits / Employee
-$1,212,607
Market Cap
3.53B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APGE News
- 13 days ago - Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million - GlobeNewsWire
- 14 days ago - Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 14 days ago - Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 15 days ago - Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 6 weeks ago - Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress - GlobeNewsWire
- 7 weeks ago - Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis - Seeking Alpha